LivaNova beats estimates for Q2 revenue, raises FY guidance
Overview
LivaNova Q2 2025 revenue rises 10.7%, beating analyst expectations, per LSEG data
Adjusted EPS of $1.05 beats estimates, reflecting strong operational performance
Company raises full-year 2025 guidance for revenue, adjusted EPS and free cash flow
Outlook
LivaNova raises 2025 revenue growth guidance to 8%-9% constant-currency
Company expects 2025 adjusted EPS between $3.70 and $3.80
LivaNova projects 2025 adjusted free cash flow of $140 mln to $160 mln
Company sees foreign currency as a tailwind of approximately 1% for 2025
Result Drivers
CARDIOPULMONARY DEMAND - Strong demand for consumables and Essenz Perfusion System drove Cardiopulmonary revenue growth
NEUROMODULATION PERFORMANCE - Solid performance across all regions contributed to Neuromodulation revenue increase
OPERATING MARGIN EXPANSION - Disciplined execution led to meaningful operating margin expansion, per CEO Vladimir Makatsaria
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $352.50 mln | $332.30 mln (8 Analysts) |
Q2 Adjusted EPS | Beat | $1.05 | $0.86 (8 Analysts) |
Q2 EPS | $0.5 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for LivaNova PLC is $58.00, about 26.5% above its August 5 closing price of $42.61
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago
Press Release:
